Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36

Anders Ettrup; Søren Holm; Martin Hansen; Muhammad Wasim; Martin Andreas Santini; Mikael Palner; Jacob Madsen; Claus Svarer; Jesper Langgaard Kristensen; Gitte Moos Knudsen

doi:10.1007/s11307-012-0609-4

Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36

Anders Ettrup, Søren Holm, Martin Hansen, Muhammad Wasim, Martin Andreas Santini, Mikael Palner, Jacob Madsen, Claus Svarer, Jesper Langgaard Kristensen, Gitte Moos Knudsen

46 Citationer (Scopus)

Abstract

[11C]Cimbi-36 was recently developed as an agonist radioligand for brain imaging of serotonin 2A receptors (5-HT2A) with positron emission tomography (PET). This may be used to quantify the high-affinity state of 5-HT2A receptors and may have the potential to quantify changes in cerebral 5-HT levels in vivo. We here investigated safety aspects related to clinical use of [11C]Cimbi-36, including radiation dosimetry and in vivo pharmacology.

Originalsprog	Engelsk
Tidsskrift	Molecular Imaging and Biology
Vol/bind	15
Udgave nummer	4
Sider (fra-til)	376-83
Antal sider	8
ISSN	1536-1632
DOI	https://doi.org/10.1007/s11307-012-0609-4
Status	Udgivet - aug. 2013

Adgang til dokumentet

10.1007/s11307-012-0609-4

Citationsformater

@article{c80d3f8c1ea54d3e90ad4956ce270899,

title = "Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36",

abstract = "[11C]Cimbi-36 was recently developed as an agonist radioligand for brain imaging of serotonin 2A receptors (5-HT2A) with positron emission tomography (PET). This may be used to quantify the high-affinity state of 5-HT2A receptors and may have the potential to quantify changes in cerebral 5-HT levels in vivo. We here investigated safety aspects related to clinical use of [11C]Cimbi-36, including radiation dosimetry and in vivo pharmacology.",

author = "Anders Ettrup and S{\o}ren Holm and Martin Hansen and Muhammad Wasim and Santini, {Martin Andreas} and Mikael Palner and Jacob Madsen and Claus Svarer and Kristensen, {Jesper Langgaard} and Knudsen, {Gitte Moos}",

year = "2013",

month = aug,

doi = "10.1007/s11307-012-0609-4",

language = "English",

volume = "15",

pages = "376--83",

journal = "Molecular Imaging and Biology",

issn = "1536-1632",

publisher = "Springer New York LLC",

number = "4",

}

TY - JOUR

T1 - Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36

AU - Ettrup, Anders

AU - Holm, Søren

AU - Hansen, Martin

AU - Wasim, Muhammad

AU - Santini, Martin Andreas

AU - Palner, Mikael

AU - Madsen, Jacob

AU - Svarer, Claus

AU - Kristensen, Jesper Langgaard

AU - Knudsen, Gitte Moos

PY - 2013/8

Y1 - 2013/8

N2 - [11C]Cimbi-36 was recently developed as an agonist radioligand for brain imaging of serotonin 2A receptors (5-HT2A) with positron emission tomography (PET). This may be used to quantify the high-affinity state of 5-HT2A receptors and may have the potential to quantify changes in cerebral 5-HT levels in vivo. We here investigated safety aspects related to clinical use of [11C]Cimbi-36, including radiation dosimetry and in vivo pharmacology.

AB - [11C]Cimbi-36 was recently developed as an agonist radioligand for brain imaging of serotonin 2A receptors (5-HT2A) with positron emission tomography (PET). This may be used to quantify the high-affinity state of 5-HT2A receptors and may have the potential to quantify changes in cerebral 5-HT levels in vivo. We here investigated safety aspects related to clinical use of [11C]Cimbi-36, including radiation dosimetry and in vivo pharmacology.

U2 - 10.1007/s11307-012-0609-4

DO - 10.1007/s11307-012-0609-4

M3 - Journal article

C2 - 23306971

SN - 1536-1632

VL - 15

SP - 376

EP - 383

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

IS - 4

ER -

Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater